Thursday, March 14, 2019 10:18:54 AM
The agreements if you will, between USA/Russia/Ukraine/Japan are mutually accepted standards for clinical trials. Meaning, a clinical trial process in any one of the nearly 60 countries listed agree to accept each others findings, provided ALL the proper documentation is in order.
With Repurposed Drugs, they don't have to go back to the drawing board, because that same drug has already proven itself to be safe for Humans or Animals. Phase 1 of said process already has documented proof regarding the drugs Safety and Dosages.
Therefore, the drug now only has to prove it will work for another targeted purpose other than it's original intent. The Phase II and III trials does just that. Proves the drug works for something else.
It's not rocket science to understand that Drug Repurposing does not require certain levels of redundancy. The global agreements in place provides the scientific community a minimum level of cooperation so everyone isnt running around like a chicken with their head cut off.
Your method of thinking would create nothing but chaos versus uniformity- LAW & ORDER.
Bottom line goes back to the topline...you're not interested in facts. Just drama. Have at it mate. I'll keep doing what I have to do here. Which is offer folks something worth their time.
/////AMG
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM